Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 55Gastrointestinal 28Breast 13Sarcoma 12Gynecologic 9CNS 7Head & Neck 5Endocrine 5Other solid neoplasm 4NET 2Genitourinary 2Tumor-Agnostic 1Dermatologic 1

Conditions

Melanoma 1

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × anlotinib × Dermatologic × Clear all
NCT04979585 2021-08-03

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

The First Hospital of Jilin University

Phase 2 Unknown
66 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡